Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study

Oldenborg, S.; Os, Rob M. van; Rij, Caroline M. van; Crezee, J.; Kamer, Jeroen B. van de; Rutgers, Emiel J.; Geijsen, Elisabeth D.; Vörding, Paul J. Zum Vörde Sive; Koning, Caro C.E.; Tienhoven, Geertjan van

doi:10.3109/02656730903341340

Cited by 40 publications

(55 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of re-irradiation plus hyperthermia was reported by Oldenborg et al [36 ]in 2010. 78 patients with breast recurrences were treated with the combined treatment and responded to the therapy.…”

Section: Resultsmentioning

confidence: 98%

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

et al. 2015

View full text Add to dashboard Cite

Background: Hyperthermia has been included in the 2013 National Comprehensive Cancer Network (NCCN) guidelines as an option for the treatment of breast recurrences. The purpose of this article is to demonstrate the important role of hyperthermia as a therapeutic modality by presenting clinical trials on this subject carried out in the last decades. Materials and Methods: All relevant trials published since 1987 were retrieved from Medline and reviewed. Results: Results show that the addition of hyperthermia to radiotherapy and/or chemotherapy for the treatment of breast cancer enhances treatment response and can increase local control. Conclusion: Further studies are required to evaluate potential benefits of hyperthermia in the treatment of other kinds of superficial tumors.

show abstract

Section: Resultsmentioning

confidence: 98%

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Radiotherapy at the AMC typically consisted of 32 Gy in 8 fractions given twice per week over a period of 4 weeks; at the BVI, patients received 36 Gy in 12 fractions given 4 times per week. The radiation techniques applied were similar to the standard techniques used for the treatment of recurrent breast cancer, usually photons (6 MV or 10 MV) for the lateral chest wall, axillary, and periclavicular area and electrons (8)(9)(10)(11)(12)(13)(14)(15) MeV) for the anterior chest wall. Hyperthermia was given once per week within 1 hour of radiotherapy at AMC or twice weekly at BVI (Tables 3 and 4).…”

Section: Methodsmentioning

confidence: 99%

“…[9][10][11] Hyperthermia is used frequently to boost the relatively low maximally permitted radiotherapy dose in the treatment of recurrences of breast cancer in previously irradiated areas. [12][13][14] In total, 16 patients with RAS received RT-HT at our institutes. Two of these 16 patients were reported previously in a case report and a letter.…”

mentioning

confidence: 99%

Reirradiation and hyperthermia for radiation‐associated sarcoma

Jong

Oldenborg

Oei

et al. 2011

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to evaluate the role of reirradiation and hyperthermia in the treatment of radiation-associated sarcoma (RAS) in the thoracic region, which is an increasing, yet extremely rare condition with a poor prognosis. METHODS: Between 1979 and 2009, 16 patients with RAS in the thoracic region were treated in the Academic Medical Center and the Institute Verbeeten with reirradiation and hyperthermia. In 13 patients, this treatment was given for unresectable disease and 3 times after resection as adjuvant treatment. The median latency period between the original malignancy diagnosis and the RAS diagnosis was 86 months (range 19-212 months). Histology was angiosarcoma in 11 patients (69%). The literature on reirradiation with or without hyperthermia for RAS was reviewed. RESULTS: The median survival was 15.5 months (range, 3-204 months). Four patients were not evaluable for response. The response rate for the remaining 12 patients was 75% (7 complete responses and 2 partial responses). Six patients remained free of local failure until death (5 months and 7 months) or last follow-up (8 months, 11 months, 39 months, and 68 months). CONCLUSIONS: The current study indicates that combined reirradiation and hyperthermia for RAS in the thoracic region is feasible. The high response rate and the possibility of durable local control suggest that this treatment is promising. Cancer 2012;118:180-

show abstract

“…Several publications have suggested that hyperthermia with low-dose re-irradiation can achieve good local control for patients who have had all macroscopic disease eradicated prior to radiotherapy. [3–5]. In the present study we evaluate elective thermoradiotherapy for patients who have had no prior radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous radiotherapy and superficial hyperthermia for high-risk breast carcinoma: A randomised comparison of treatment sequelae in heated versus non-heated sectors of the chest wall hyperthermia

Varma

Myerson

Moros

et al. 2012

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose In vitro data demonstrate that heat-induced radiosensitisation is maximised if hyperthermia and radiotherapy are given simultaneously, with the radiation fraction delivered midway through a hyperthermia session, rather than sequentially. The long-term normal tissue toxicity of full-dose simultaneous thermoradiotherapy is unknown. Materials and methods Patients with locally advanced breast cancer (T3, T4 or more than three involved nodes or local recurrence), no prior radiotherapy, received between four and eight sessions of simultaneous thermoradiotherapy. Hyperthermia always included the primary tumour site. In addition an electively heated sector (EHS) was included. The EHS was randomised to either medial or lateral to the tumour site, with the other side an irradiated but unheated control. As per our usual practice, patients received surgery and/or chemotherapy prior to radiotherapy. Radiation doses were 46–50 Gy followed by a boost of ≤16 Gy at 1.8–2 Gy per fraction. EHS and control sectors received the same dose. Results A total of 57 evaluable cases with average follow-up of 79 months experienced two local and two nodal recurrences. There was no significant difference in ≥grade 2 toxicity for heated versus control sectors (LR χ2 = 0.78, p = 0.38) with no relationship between number of hyperthermia sessions and toxicity (LR χ2 = 2.90, p = 0.09). Conclusions Simultaneous full-dose thermoradiotherapy for breast cancer is feasible and well tolerated, with no significant difference in late toxicity between electively heated and unheated control sectors. All patients had hyperthermia to the primary tumour site with excellent local control.

show abstract

Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study

Abstract: For patients experiencing local recurrence in a previously radiated area, re-irradiation plus hyperthermia following minimisation of tumour burden leads to a high rate of local control, albeit with significant toxicity. The latter might be reduced by a more fractionated re-RT schedule.

Cited by 40 publications

References 35 publications

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data

Reirradiation and hyperthermia for radiation‐associated sarcoma

Simultaneous radiotherapy and superficial hyperthermia for high-risk breast carcinoma: A randomised comparison of treatment sequelae in heated versus non-heated sectors of the chest wall hyperthermia

Contact Info

Product

Resources

About